Loading
A phase 3 trial of Datopotamab deruxtecan, Osimertinib, Pemetrexed in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. ClinicalTrials.gov record last updated 2026-05-14: recruiting. Enrollment is planned at 744 participants. Primary completion is estimated at 2026-09-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin. Registered primary measures: Progression free Survival (PFS).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Osimertinib, AstraZeneca.
Shares Osimertinib, Pemetrexed, AstraZeneca, Cisplatin.
Shares Osimertinib, Pemetrexed, AstraZeneca, Cisplatin.
Shares Datopotamab deruxtecan, TROP2, Pemetrexed, Small-cell lung cancer.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin.
Shares Datopotamab deruxtecan, TROP2, Pemetrexed, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/